Keywords
Molecular design
Delivery systems
Immune mechanisms
Submitted : 2025-03-04
Accepted : 2025-03-19
Published : 2025-04-03
Abstract
Since the outbreak of COVID-19, mRNA vaccine technology has achieved groundbreaking advancements. Characterized by its high safety profile and potent immune activation capabilities, this technology has demonstrated significant potential in the prevention of infectious diseases and cancer therapeutics, marking a new milestone in vaccine development. This review focuses on three key aspects—molecular design, delivery systems, and immunological mechanisms—providing a comprehensive analysis of structural optimization strategies, delivery methodologies, and immune modulation approaches for mRNA vaccines. Additionally, it summarizes and evaluates potential challenges that may arise in the future development of mRNA vaccines. By analyzing existing technological pathways, this review aims to advance innovation in mRNA vaccine technology and facilitate its broad applications in public health and veterinary medicine.
References
Zhou W, Jiang L, Liao S, et al., 2023, Vaccines’ New Era-RNA Vaccine. Viruses, 15(8): 1760.
Sahin U, Kariko K, Tureci O, 2014, mRNA-Based Therapeutics—Developing a New Class of Drugs. Nat Rev Drug Discov, 13(10): 759–780.
Teo SP, 2022, Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. J Pharm Pract, 35(6): 947–951.
Fang E, Liu X, Li M, et al., 2022, Advances in COVID-19 mRNA Vaccine Development. Signal Transduct Target Ther, 7(1): 94.
Corbett KS, Edwards DK, Leist SR, et al., 2020, SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness. Nature, 586(7830): 567–571.
Sahin U, Muik A, Derhovanessian E, et al., 2020, COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses. Nature, 586(7830): 594–599.
Kozak M, 1987, At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells. J Mol Biol, 196(4): 947–950.
Mayr C, 2019, What Are 3’ UTRs Doing? Cold Spring Harb Perspect Biol, 11(10): a034728.
Wadhwa A, Aljabbari A, Lokras A, et al., 2020, Opportunities and Challenges in the Delivery of mRNA-Based Vaccines. Pharmaceutics, 12(2): 102.
Kariko K, Muramatsu H, Keller JM, et al., 2012, Increased Erythropoiesis in Mice Injected with Submicrogram Quantities of Pseudouridine-Containing mRNA Encoding Erythropoietin. Mol Ther, 20(5): 948–953.
Gustafsson C, Govindarajan S, Minshull J, 2004, Codon Bias and Heterologous Protein Expression. Trends Biotechnol, 22(7): 346–353.
Grier AE, Burleigh S, Sahni J, et al., 2016, pEVL: A Linear Plasmid for Generating mRNA IVT Templates with Extended Encoded Poly(A) Sequences. Mol Ther Nucleic Acids, 5(4): e306.
Lima SA, Chipman LB, Nicholson AL, et al., 2017, Short poly(A) Tails Are a Conserved Feature of Highly Expressed Genes. Nat Struct Mol Biol, 24(12): 1057–1063.
Xia X, 2021, Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines. Vaccines (Basel), 9(7): 734.
Mckay PF, Hu K, Blakney AK, et al., 2020, Self-Amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice. Nat Commun, 11(1): 3523.
Fuller DH, Berglund P, 2020, Amplifying RNA Vaccine Development. N Engl J Med, 382(25): 2469–2471.
Beissert T, Perkovic M, Vogel A, et al., 2020, A Trans-Amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity. Mol Ther, 28(1): 119–128.
Kristensen LS, Andersen MS, Stagsted LVW, et al., 2019, The Biogenesis, Biology and Characterization of Circular RNAs. Nat Rev Genet, 20(11): 675–691.
Chen R, Wang SK, Belk JA, et al., 2023, Engineering Circular RNA for Enhanced Protein Production. Nat Biotechnol, 41(2): 262–272.
Phua KKL, Leong KW, Nair SK, 2013, Transfection Efficiency and Transgene Expression Kinetics of mRNA Delivered in Naked and Nanoparticle Format. J Control Release, 166(3): 227–233.
Van Lint S, Goyvaerts C, Maenhout S, et al., 2012, Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy. Cancer Res, 72(7): 1661–1671.
Abbasi S, Matsui-Masai M, Yasui F, et al., 2024, Carrier-Free mRNA Vaccine Induces Robust Immunity Against SARS-CoV-2 in Mice and Non-Human Primates Without Systemic Reactogenicity. Mol Ther, 32(5): 1266–1283.
Neumann E, Schaefer-Ridder M, Wang Y, et al., 1982, Gene Transfer into Mouse Lyoma Cells by Electroporation in High Electric Fields. EMBO J, 1(7): 841–845.
Aarntzen EHJG, Schreibelt G, Bol K, et al., 2012, Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clin Cancer Res, 18(19): 5460–5470.
Sun X, Zeng L, Huang Y, 2019, Transcutaneous Delivery of DNA/mRNA for Cancer Therapeutic Vaccination. J Gene Med, 21(7): e3089.
Pardi N, Hogan MJ, Porter FW, et al., 2018, mRNA Vaccines—A New Era in Vaccinology. Nat Rev Drug Discov, 17(4): 261–279.
Qiu P, Ziegelhoffer P, Sun J, et al., 1996, Gene Gun Delivery of mRNA In Situ Results in Efficient Transgene Expression and Genetic Immunization. Gene Ther, 3(3): 262–268.
Peking P, Koller U, Hainzl S, et al., 2016, A Gene Gun-Mediated Nonviral RNA Trans-Splicing Strategy for Col7a1 Repair. Mol Ther Nucleic Acids, 5: e287.
Samulski RJ, Muzyczka N, 2014, AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. Annu Rev Virol, 1(1): 427–451.
Kay MA, Glorioso JC, Naldini L, 2001, Viral Vectors for Gene Therapy: The Art of Turning Infectious Agents into Vehicles of Therapeutics. Nat Med, 7(1): 33–40.
Lundstrom K, 2016, Replicon RNA Viral Vectors as Vaccines. Vaccines (Basel), 4(4).
Beck JD, Reidenbach D, Salomon N, et al., 2021, mRNA Therapeutics in Cancer Immunotherapy. Mol Cancer, 20(1): 69.
Gu Y-Z, Zhao X, Song X-R, 2020, Ex Vivo Pulsed Dendritic Cell Vaccination Against Cancer. Acta Pharmacol Sin, 41(7): 959–969.
Pardi N, Tuyishime S, Muramatsu H, et al., 2015, Expression Kinetics of Nucleoside-Modified mRNA Delivered in Lipid Nanoparticles to Mice by Various Routes. J Control Release, 217: 345–351.
Cui S, Wang Y, Gong Y, et al., 2018, Correlation of the Cytotoxic Effects of Cationic Lipids with Their Headgroups. Toxicol Res (Camb), 7(3): 473–479.
Patel P, Ibrahim NM, Cheng K, 2021, The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA. Trends Pharmacol Sci, 42(6): 448–460.
Schlosser K, Taha M, Deng Y, et al., 2018, Systemic Delivery of MicroRNA Mimics with Polyethylenimine Elevates Pulmonary MicroRNA Levels, but Lacks Pulmonary Selectivity. Pulm Circ, 8(1): 2045893217750613.
Ulkoski D, Bak A, Wilson JT, et al., 2019, Recent Advances in Polymeric Materials for the Delivery of RNA Therapeutics. Expert Opin Drug Deliv, 16(11): 1149–1167.
Ke X, Shelton L, Hu Y, et al., 2020, Surface-Functionalized PEGylated Nanoparticles Deliver Messenger RNA to Pulmonary Immune Cells. ACS Appl Mater Interfaces, 12(32): 35835–35844.
Ding X, Wang A, Tong W, et al., 2019, Biodegradable Antibacterial Polymeric Nanosystems: A New Hope to Cope with Multidrug-Resistant Bacteria. Small, 15(20): e1900999.
Jarzebska N T, Mellett M, Frei J, et al., 2021, Protamine-Based Strategies for RNA Transfection. Pharmaceutics, 13(6): 877.
Papachristofilou A, Hipp MM, Klinkhardt U, et al., 2019, Phase Ib Evaluation of a Self-Adjuvanted Protamine Formulated mRNA-Based Active Cancer Immunotherapy, BI1361849 (CV9202), Combined with Local Radiation Treatment in Patients with Stage IV Non-Small Cell Lung Cancer. J Immunother Cancer, 7(1): 38.
Alberer M, Gnad-Vogt U, Hong HS, et al., 2017, Safety and Immunogenicity of a mRNA Rabies Vaccine in Healthy Adults: An Open-Label, Non-Randomized, Prospective, First-in-Human Phase 1 Clinical Trial. Lancet, 390(10101): 1511–1520.
Pardi N, Hogan MJ, Weissman D, 2020, Recent Advances in mRNA Vaccine Technology. Curr Opin Immunol, 65: 14–20.
Van Den Brand D, Gorris MAJ, Van Asbeck AH, et al., 2019, Peptide-Mediated Delivery of Therapeutic mRNA in Ovarian Cancer. Eur J Pharm Biopharm, 141: 180–190.
Hasannejad-Asl B, Pooresmaeil F, Takamoli S, et al., 2022, Cell Penetrating Peptide: A Potent Delivery System in Vaccine Development. Front Pharmacol, 13: 1072685.
Ho W, Gao M, Li F, et al., 2021, Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery. Adv Healthc Mater, 10(8): e2001812.
Cullis PR, Hope MJ, 2017, Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol Ther, 25(7): 1467–1475.
Awasthi S, Hook LM, Pardi N, et al., 2019, Nucleoside-Modified mRNA Encoding HSV-2 Glycoproteins C, D, and E Prevents Clinical and Subclinical Genital Herpes. Sci Immunol, 4(39): eaaw7083.
Pardi N, Hogan MJ, Pelc RS, et al., 2017, Zika Virus Protection by a Single Low-Dose Nucleoside-Modified mRNA Vaccination. Nature, 543(7644): 248–251.
Li F, Zhang X Q, Ho W, et al., 2023, mRNA Lipid Nanoparticle-Mediated Pyroptosis Sensitizes Immunologically Cold Tumors to Checkpoint Immunotherapy. Nat Commun, 14(1): 4223.
Li W, Huang M, Wu Z, et al., 2024, mRNA-Lipid Nanoparticle-Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple-Negative Breast Cancer. Adv Sci (Weinh), 11(32): e2309988.
Eygeris Y, Gupta M, Kim J, et al., 2022, Chemistry of Lipid Nanoparticles for RNA Delivery. Acc Chem Res, 55(1): 2–12.
Sebastiani F, Yanez Arteta M, Lerche M, et al., 2021, Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of mRNA-Containing Lipid Nanoparticles. ACS Nano, 15(4): 6709–6722.
Cheng Q, Wei T, Farbiak L, et al., 2020, Selective Organ Targeting (SORT) Nanoparticles for Tissue-Specific mRNA Delivery and CRISPR-Cas Gene Editing Nat Nanotechnol, 15(4): 313–320.
Kowalski PS, Rudra A, Miao L, et al., 2019, Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Mol Ther, 27(4): 710–728.
Pollard C, Rejman J, De Haes W, et al., 2013, Type I IFN Counteracts the Induction of Antigen-Specific Immune Responses by Lipid-Based Delivery of mRNA Vaccines. Mol Ther, 21(1): 251–259.
Corbett KS, Flynn B, Foulds KE, et al., 2020, Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med, 383(16): 1544–1555.
Espeseth AS, Cejas PJ, Citron MP, et al., 2020, Modified mRNA/Lipid Nanoparticle-Based Vaccines Expressing Respiratory Syncytial Virus F Protein Variants are Immunogenic and Protective in Rodent Models of RSV Infection. NPJ Vaccines, 5(1): 16.
Liang F, Lindgren G, Lin A, et al., 2017, Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques. Molecular Therapy, 25(12): 2635–2647.
Lindgren G, Ols S, Liang F, et al., 2017, Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells. Front Immunol, 8: 1539.
Singh A, 2021, Eliciting B Cell Immunity Against Infectious Diseases Using Nanovaccines. Nature Nanotechnology, 16(1): 16–24.
Lederer K, Castano D, Gomez Atria D, et al., 2020, SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity, 53(6): 1281–1295.
Pardi N, Hogan MJ, Naradikian MS, et al., 2018, Nucleoside-Modified mRNA Vaccines Induce Potent T Follicular Helper and Germinal Center B Cell Responses. J Exp Med, 215(6): 1571–1588.
Turner JS, O’halloran JA, Kalaidina E, et al., 2021, SARS-CoV-2 mRNA Vaccines Induce Persistent Human Germinal Centre Responses. Nature, 596(7870): 109–113.
Doria-Rose N, Suthar MS, Makowski M, et al., 2021, Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for COVID-19. N Engl J Med, 384(23): 2259–2261.
Yuan M, Huang D, Lee C-CD, et al., 2021, Structural and Functional Ramifications of Antigenic Drift in Recent SARS-CoV-2 Variants. Science, 373(6556): 818–823.
Wang Z, Schmidt F, Weisblum Y, et al., 2021, mRNA Vaccine-Elicited Antibodies to SARS-CoV-2 and Circulating Variants. Nature, 592(7855): 616–622.
Feldman RA, Fuhr R, Smolenov I, et al., 2019, mRNA Vaccines against H10N8 and H7N9 Influenza Viruses of Pandemic Potential are Immunogenic and Well Tolerated in Healthy Adults in Phase 1 Randomized Clinical Trials. Vaccine, 37(25): 3326–3334.
Shimabukuro TT, Cole M, Su JR, 2021, Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA, 325(11): 1101–1102.
Besin G, Milton J, Sabnis S, et al., 2019, Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties. Immunohorizons, 3(7): 282–293.
Kozma GT, Shimizu T, Ishida T, et al., 2020, Anti-PEG Antibodies: Properties, Formation, Testing and Role in Adverse Immune Reactions to PEGylated Nano-Biopharmaceuticals. Adv Drug Deliv Rev, (154–155): 163–175.
Zhang N-N, Li X-F, Deng Y-Q, et al., 2020, A Thermostable mRNA Vaccine against COVID-19. Cell, 182(5): 1271–1283.
Qi Y, Fox CB, 2021, Development of Thermostable Vaccine Adjuvants. Expert Rev Vaccines, 20(5): 497–517.
Mestas J, Hughes CCW, 2004, Of Mice and Not Men: Differences Between Mouse and Human Immunology. J Immunol, 172(5): 2731–2738.
Brodin P, Davis MM, 2017, Human Immune System Variation. Nat Rev Immunol, 17(1): 21–29.
Renu S, Feliciano-Ruiz N, Lu F, et al., 2020, A Nanoparticle-Poly(I:C) Combination Adjuvant Enhances the Breadth of the Immune Response to Inactivated Influenza Virus Vaccine in Pigs. Vaccines (Basel), 8(2): 229.
Fujimoto Y, Hatoya S, Sugiura K, et al., 2024, Toll-Like Receptor 3-Stimulation and Aggregate-Formation Synergistically Enhances Anti-Inflammatory Activity of Feline Mesenchymal Stem Cells. J Vet Sci, 25(6): e86.
Ohta H, Ezoe S, Yamazaki K, et al., 2009, Application of Aluminum Hydroxide for an In Ovo Live Newcastle Disease Vaccine. Avian Dis, 53(3): 392–395.
De Gregorio E, Tritto E, Rappuoli R, 2008, Alum Adjuvanticity: Unraveling a Century Old Mystery. Eur J Immunol, 38(8): 2068–2071.
Wang T, Ma X, Lei Y, et al., 2016, Solid Lipid Nanoparticles Coated with Cross-Linked Polymeric Double Layer for Oral Delivery of Curcumin. Colloids Surf B Biointerfaces, 148: 1–11.
Wang T, Xue J, Hu Q, et al., 2017, Preparation of Lipid Nanoparticles with High Loading Capacity and Exceptional Gastrointestinal Stability for Potential oral Delivery Applications. J Colloid Interface Sci, 507: 119–130.
D’Souza AA, Shegokar R, 2016, Polyethylene Glycol (PEG): A Versatile Polymer for Pharmaceutical Applications. Expert Opin Drug Deliv, 13(9): 1257–1275.